Univar Inc. announced today that its wholly-owned subsidiary, Univar USA Inc., has acquired all of the outstanding stock of Arrow Chemical, Inc., an importer and distributor of active pharmaceutical ingredients (API) and other specialty chemistries in the U.S. market.
Founded in 1982, Arrow Chemical sources a broad range of APIs, and nutritional and cosmetic ingredients from a broad network of suppliers in Asia, Western Europe, and the U.S. The company specializes in fine, niche chemistries, and works with customers and suppliers across the world in third-party manufacturing, custom chemical synthesis, finished dosage, and Abbreviated New Drug Application (ANDA) developments. Arrow Chemical is based in Greenwich, Conn., and services customers with truck, rail, and tanker deliveries through a nationwide third-party distribution network.
“We see strong growth opportunities for Univar in the pharmaceutical and nutraceutical market, and continue to focus our commercial capabilities for delivering a total solution set of products and services to customers,” said Univar President and Chief Executive Officer Erik Fyrwald. “Arrow Chemical has a strong base business with key pharmaceutical manufacturers and has built a solid global network of quality and reputable ingredient producers. This acquisition enhances the value we can deliver to our customers by expanding our existing offering with a complementary portfolio of APIs and other specialty ingredients essential to the formulation of generic and over-the-counter pharmaceuticals.”
“For more than 30 years, Arrow Chemical has been a business built around delivering outstanding service and value to our customers,” said Gary Trief, President, Arrow Chemical. “As we looked ahead to the future, we saw Univar as the ideal opportunity for providing the resources, talent, and unique global reach to expand and enhance what we can currently offer to our customers and suppliers. We look forward to leveraging the best of Arrow Chemical to help build a leadership role for Univar within the generic and OTC pharmaceutical ingredient market.”
France has launched an offshore green hydrogen production platform at the country’s Port of Saint-Nazaire this week, along with its first offshore wind farm. The hydrogen plant, which its operators say is the world’s first facility of its type, coincides with the launch of another “first of its kind” facility in Sweden dedicated to storing hydrogen in an underground lined rock cavern (LRC).
The project sets up the Hydrogen Valley in Rome, the first industrial-scale technological hub for the development of the national supply chain for the production, transport, storage and use of hydrogen for the decarbonization of industrial processes and for sustainable mobility.
At first glance, hydrogen seems to be the perfect solution to our energy needs. It doesn’t produce any carbon dioxide when used. It can store energy for long periods of time. It doesn’t leave behind hazardous waste materials, like nuclear does. And it doesn’t require large swathes of land to be flooded, like hydroelectricity. Seems too good to be true. So…what’s the catch?